Diabetes News

NASHVILLE, Tenn. — Only about one in 20 women with type 1 diabetes received preconception counseling, according to data presented at the American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting.

The FDA has granted breakthrough device designation to RenalytixAI’s artificial intelligence-enabled clinical diagnostic for kidney disease, known as KidneyIntelX, according to a press release from Mount Sinai, a collaborator on the project.

PHILADELPHIA — Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have been shown to be safe and effective second-line therapy in managing diabetes in multiple clinical trials, but clinicians need to consider their side effect profile when they are used in patients with chronic kidney disease, according to a speaker at the American College of Physicians Internal Medicine Meeting.

Canagliflozin safely reduced the risk of kidney failure and prevented cardiovascular events in patients with type 2 diabetes and chronic kidney disease, according to phase 3 results from the CREDENCE study presented at a late-breaking clinical trials session at the International Society of Nephrology’s World Congress of Nephrology Annual Meeting in Melbourne, Australia.

Janssen on Thursday submitted a supplemental new drug application to the FDA seeking a new indication for the SGLT2 inhibitor canagliflozin to reduce the risk for end-stage renal disease, the doubling of serum creatinine, and renal or cardiovascular death in adults with type 2 diabetes and chronic kidney disease, according to a press release from the company.

March may be National Nutrition Month, but the way to obtain a healthy lifestyle through nutrition, or the determinants certain foods and drinks can cause, is the subject of research throughout the year.

Between 2002 and 2013, the annual incidence of ESKD increased among nonindigenous Australians with type 2 diabetes but was stable for those with type 1, according to a study published in American Journal of Kidney Diseases.

The dialysis and transplant community could be treating more than 1 million people for ESRD by the year 2030 as improved efforts to reduce mortality lose the battle against the spread of obesity and escalating hypertension and diabetes.

Renal arteriosclerosis increases the risk for both renal composite and cardiovascular events in Japanese adults with type 2 diabetes and diabetic nephropathy regardless of the presence of hypertension, according to findings published in the Journal of Diabetes Investigation.

A “substantial gap” existed in primary care physicians’ adherence to several American Diabetes Association guidelines for monitoring diabetes, according to findings recently published in Family Medicine and Community Health.